Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Salarius Pharmaceuticals Inc shares valued at $16,000 were purchased by Rosenblum Mark J on Nov 20 ’25. At $0.80 per share, Rosenblum Mark J acquired 20,000 shares. The insider’s holdings grew to 20,177 shares worth approximately $15132.75 following the completion of this transaction.
As published in their initiating research note from Ladenburg Thalmann on April 27, 2020, Salarius Pharmaceuticals Inc [SLRX] has been a Buy and the price target has been revised to $3.80.
Analyzing SLRX Stock Performance
On last trading session, Salarius Pharmaceuticals Inc [NASDAQ: SLRX] plunged -4.61% to $0.75. The stock’s lowest price that day was $0.7191, but it reached a high of $0.8132 in the same session. During the last five days, there has been a drop of approximately -38.06%. Over the course of the year, Salarius Pharmaceuticals Inc shares have dropped approximately -96.38%. Shares of the company reached a 52-week high of $108.0000 on 01/13/25 and a 52-week low of $0.7106 on 11/19/25.
Support And Resistance Levels for Salarius Pharmaceuticals Inc (SLRX)
According to the 24-hour chart, there is a support level at 0.7074, which, if violated, would cause prices to drop to 0.6653. In the upper region, resistance lies at 0.8033. The next price resistance is at 0.8571. RSI (Relative Strength Index) is 18.74 on the 14-day chart, showing oversold technical sentiment.
Is Salarius Pharmaceuticals Inc subject to short interest?
Stocks of Salarius Pharmaceuticals Inc saw a sharp rise in short interest on 2025-10-31 jumping by 0.24 million shares to 0.36 million. Data from Yahoo Finance shows that the short interest on 2025-09-30 was 0.12 million shares. A jump of 67.51% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 1.48 of the overall float, the days-to-cover ratio (short ratio) jumped to 1.48.
